John David Chetwood
1* 
, Lin Lin Myat
1 , Helen Lammi
1, Mani Panat
1 , James Hughes
1 1 Department of General Medicine, Tamworth Hospital, Dean St, Tamworth, NSW, Australia
Abstract
We report a case of acute kidney injury (AKI) secondary to immune-mediated acute interstitial nephritis (AIN), with supporting diagnostic results and a successful response to treatment. This entity is gaining increasing recognition with the burgeoning use of immunotherapy agents in oncology. The timeline for the development of AIN from the initiation of immunotherapy varies, and may range in severity from asymptomatic to severe, organ-threatening and with life threatening consequences. Renal biopsy should be performed to confirm the diagnosis due to the potential impact of discontinuation of immunotherapy on cancer survival. Re-challenge with immunotherapy is reasonable once renal function recovers.
Implication for health policy/practice/research/medical education:
Immune-mediated acute interstitial nephritis is the most commonly reported etiology for acute kidney injury related to immune checkpoint inhibitors.
Please cite this paper as: Chetwood JD, Myat LL, Lammi H, Panat M, Hughes J. Acute interstitial nephritis with immunotherapy; a growing entity? J Renal Inj Prev. 2020; 9(4): e35. doi: 10.34172/jrip.2020.35.